MGMT and neoplasm: There were no differences in MGMT promotor methylation status, first-line therapy, or pre- and postoperative tumor volumes (both for contrast-enhancing and noncontrast-enhancing tumor) between IDHwt/TERTmut and IDHwt/TERTwt patients (Figure 1A and B).